Share on LinkedInShare on LinkedIn

ARTICLE · 14 OCTOBER 2015

The Trans-Pacific Partnership: Changes For Patents And Pharmaceuticals?

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

Changes may be on the horizon for Canada's legal and regulatory regime for patents and pharmaceuticals.

CanadaIntellectual Property

Changes may be on the horizon for Canada's legal and regulatory regime for patents and pharmaceuticals. Included in the Trans-Pacific Partnership Agreement (TPP), concluded Oct. 5, 2015 are negotiated outcomes for the protection and enforcement of intellectual property (IP) rights that may change the legal and regulatory landscape for the pharmaceutical industry.

The text of the TPP agreement has not yet been released, however, the Department of Foreign Affairs recently published two documents of interest to pharmaceutical industry stakeholders: (1) a technical summary of the IP outcomes chapter of the TPP1, and (2) the anticipated benefits for Canada's life sciences industry2.

Below is a brief overview of the TPP outcomes3 and the implications they raise for the pharmaceutical industry.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from